Would you like to know if you are eligible for the Neridronate Treatment? Book your free video call now!

CRPS Treatment: pain in right leg and foot for 1.5 years

General details and patient's info

Age:37 years old at the time of treatment.
Home Country:Australia.
Illness duration:1.5 years prior to the Neridronate Treatment.
Symptoms:Burning sensation in all the leg; pain is the worst in the foot; color change on the foot; deep bone pain; change of weather is very triggering.
Clinical evaluation:CRPS. 
Time of treatment:April 2023.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient heard about Neridronate in a Facebook group and found us online when looking up the treatment. She contacted us for her first call and organized her trip with us within few months. 

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330

Clodronate infusions

3 sessions Massotherapy Rehabilitation Treatment with Physiotherapist.
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.

9 days Light Therapy (in hotel room, 30+ more minutes each day)
30 minutes or more of usage of the MTI Light Therapy reduces inflammation, increase micro-circulation, relax nerves and muscles, reduces pain transmission, accelerates healing, regenerates cells, and promotes cells activation.

Daily Report

DAY 1: Arrival at the Venise airport, greeted by her Patient Manager, followed by check-in at her Hotel in Verona. Briefing focused on the next days.

DAY 2: Rest day in the hotel, in contact with her Patient Manager.

DAY 3: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor, 1st Rehabilitation session, and 1st infusions. Tourism in Soave.

DAY 4: Morning pick-up by her Patient Manager, 2nd infusions.

DAY 5: Morning pick-up by her Patient Manager, 2nd Rehabilitation session and 3rd infusions. Tourism in Verona.

DAY 6: Rest day in the hotel, in contact with her Patient Manager.

DAY 7: Morning pick-up by her Patient Manager, 3rd Rehabilitation session, 4th infusions and 2nd visit with the Rheumatologist Professor.

DAY 8-9: Rest days in the hotel, in contact with her Patient Manager.

DAY 10: Pick-up by her Patient Manager, check-out and drop-off at the Venise airport for her trip back home.

Follow up

JULY 2023 (3 months after Neridronate treatment): The patient mentions feeling stronger and the pain seems to slowly attenuate. Color change hasn’t happened in the last month, she is very positive to see further improvements.

SEPTEMBER 2023 (5 months after Neridronate treatment): Change in color still hasn’t presented itself. Pain levels are close to zero, patient is back to her normal life.

NOVEMBER 2023 (7 months after Neridronate treatment): Patient confirms total remission of all symptoms.


This patient was able to reach full remission of her symptoms and managed to get her life back. She often calls the team as we stayed in close touch with her, and is a fervent advocate for the Neridronate infusions.

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.